{'fraction_non_alphanumeric': 0.017957351290684626, 'fraction_numerical': 0.006172839506172839, 'mean_word_length': 4.624605678233438, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
PS01.074: ENDOSCOPIC FILLING METHOD OF POLYGLYCOLIC ACID SHEETS AND FIBRIN GLUE THE LEAK FOR THE TREATMENT OF REFRACTORY ESOPHAGOGASTRIC ANASTOMOTIC LEAK AFTER ESOPHAGECTOMY


 
 
 Treatment of anastomotic leakage in the reconstruction after esophagectomy remains a challenge. Secure treatment method has been established and there is very few clinical studies. Although internal drainage using nasogastric tube has been reported recently. In this report, the authors present endoscopic filling method (EFM) for anastomotic leakage.
 
 
 
 Six patients (five males and one female) with anastomotic leakage whose ages ranged from 54 to 77 were includes in this study. The patients underwent EFM and the anastomotic leakage was filled with polyglycolic acid sheets and fibrin glue endoscopically. Initially, tube drainage was performed, and this treatment was performed as the secondary treatment, when the improvement was not made by tube drainerge.
 
 
 
 Every patient had a jejunostomy, with any concern for nutrition. Abscess was present in all patients, but external drainerge was not required. EFM was required once to five times until the fistulas cured. There was no motality. There are no cases of relapse after discharge from the hospital. Three of them cured in the first treatment, it takes average 26 days from esophagectomy to starting oral intake. This method allows us to repair for all fistula with regardless of inflammation or infection.
 
 
 
 In conclusion, the patients with reflactly esophagogastric anastomotic leakage after esophagectomy would be better served by EFM. Further study is required larger series of patients and a longer follow-up period to examine the safety and effectiveness of EFM.
 
 
 
 All authors have declared no conflicts of interest.
